Evogene Ltd. (EVGN)
Sector: Agricultural Chemicals
Industry: Biotechnology
Evogene Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.3823 | 0.3922 | 0.3301 | 0.3401 | 254,086 |
| Nov 16, 2026 | 0.3800 | 0.4404 | 0.3647 | 0.3917 | 149,021 |
| Nov 13, 2026 | 0.3680 | 0.3890 | 0.3501 | 0.3710 | 62,593 |
| Nov 12, 2026 | 0.3610 | 0.3699 | 0.3537 | 0.3610 | 49,007 |
| Nov 11, 2026 | 0.3446 | 0.4300 | 0.3340 | 0.3954 | 372,130 |
| Nov 10, 2026 | 0.2843 | 0.4150 | 0.2800 | 0.3720 | 2,364,146 |
| Nov 9, 2026 | 0.2650 | 0.2998 | 0.2650 | 0.2875 | 132,798 |
| Nov 6, 2026 | 0.2790 | 0.2819 | 0.2503 | 0.2710 | 412,935 |
| Nov 5, 2026 | 0.3403 | 0.3447 | 0.3000 | 0.3296 | 7,677,229 |
| Nov 4, 2026 | 0.3503 | 0.3642 | 0.3503 | 0.3568 | 13,187 |
| Nov 3, 2026 | 0.3610 | 0.3898 | 0.3524 | 0.3599 | 23,210 |
| Nov 2, 2026 | 0.3669 | 0.3742 | 0.3600 | 0.3610 | 25,394 |
| Oct 30, 2026 | 0.3775 | 0.3800 | 0.3653 | 0.3746 | 14,767 |
| Oct 29, 2026 | 0.3610 | 0.3811 | 0.3604 | 0.3804 | 13,846 |
| Oct 28, 2026 | 0.3600 | 0.3870 | 0.3546 | 0.3744 | 40,403 |
| Oct 27, 2026 | 0.3630 | 0.3638 | 0.3465 | 0.3638 | 9,430 |
| Oct 26, 2026 | 0.3700 | 0.3700 | 0.3604 | 0.3700 | 39,606 |
| Oct 23, 2026 | 0.3652 | 0.3726 | 0.3599 | 0.3641 | 9,397 |
| Oct 22, 2026 | 0.3594 | 0.3879 | 0.3594 | 0.3759 | 10,108 |
| Oct 21, 2026 | 0.3741 | 0.3800 | 0.3680 | 0.3704 | 38,394 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Purchase | 460.0K | $292.1K | Aug 11, 2026 | |
| Director | Purchase | 800.0K | $400.0K | Aug 4, 2026 | |
| Chief Development Officer | Purchase | 1.1K | $677.4 | Jun 4, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
L.I.A. Pure Capital Ltd. · joint filing· may incl. warrants· filed Oct 2026 | 3.1M | 16.9% | 13D |
RECANATI LEON · may incl. warrants· filed Sep 2026 | 1.4M | 7.5% | 13D |
CITADEL ADVISORS LLC | 305.5K | 1.7% | 13F |
XTX Topco Ltd | 101.9K | 0.6% | 13F |
JANE STREET GROUP, LLC | 10.8K | 0.1% | 13F |
ELDAD YARON Chief Financial Officer | 4.1K | 0.0% | FORM 4 |
MORGAN STANLEY | 2.7K | 0.0% | 13F |
Tarcic Gabi Chief Development Officer | 1.1K | 0.0% | FORM 4 |
BNP PARIBAS FINANCIAL MARKETS | 1.1K | 0.0% | 13F |
Daytona Street Capital LLC | 534 | 0.0% | 13F |
Insiders
- RECANATI LEONDirector
- Tarcic GabiChief Development Officer
- ELDAD YARONChief Financial Officer
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm.
Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components.
The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products.
The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets.
It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer.
Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
based on 18.05M shares outstanding
30d Avg
538.23K
60d Avg
2.04M
90d Avg
1.44M
Signal8's dilution snapshot of EVGN as of Dec 31, 2025 records an effective F-3 shelf registration (effective Apr 15, 2026), an at-the-market sales agreement dated Jun 11, 2026 and 2 outstanding warrant series, from SEC filings. Evogene Ltd. (NASDAQ: EVGN) traded at $0.3401 on Nov 17, 2026, down 13.17% from the previous close of $0.3917. 52-week range: $0.2503 to $1.26. The company is in the Healthcare sector (Biotechnology).